4.
KRAS突变阳性患者PD-L1表达水平与临床病理特征关系
Relationship between PD-L1 expression level and clinicopathological characteristics in KRAS mutation-positive patients
| Item | PD-L1 expression level | P | ||
| < 1.0% (n=8) | 1.0%-49.0% (n=10) | ≥50.0% (n=4) | ||
| Gender | > 0.999 | |||
| Male | 6 (75.0%) | 7 (70.0%) | 3 (75.0%) | |
| Female | 2 (25.0%) | 3 (30.0%) | 1 (25.0%) | |
| Age (yr) | 0.740 | |||
| < 65 | 5 (62.5%) | 5 (50.0%) | 3 (75.0%) | |
| ≥65 | 3 (37.5%) | 5 (50.0%) | 1 (25.0%) | |
| Smoking status | 0.039 | |||
| Former | 2 (25.0%) | 6 (60.0%) | 4 (100.0%) | |
| Never | 6 (75.0%) | 4 (40.0%) | 0 | |
| Clinical stage | 0.571 | |||
| Ⅰ | 2 (25.0%) | 1 (10.0%) | 1 (25.0%) | |
| Ⅱ | 0 | 4 (40.0%) | 1 (25.0%) | |
| Ⅲ | 1 (12.5%) | 2 (20.0%) | 1 (25.0%) | |
| Ⅳ | 5 (62.5%) | 3 (30.0%) | 1 (25.0%) | |
| Pathological type | > 0.999 | |||
| Adenocarcinoma | 8 (100.0%) | 10 (100.0%) | 4 (100.0%) | |
| Squamous carcinoma | 0 | 0 | 0 | |
| others | 0 | 0 | 0 | |